Related Experiment Videos
[Clinical studies on flomoxef in acute tonsillitis]
1Department of Otolaryngology, Suibaragou Hospital.
Abstract:
To objectively evaluate the clinical efficacy and safety in acute tonsillitis, flomoxef (FMOX) was examined for the distribution of sensitivity of clinical strains to it and for its clinical usefulness. 1. The 80% minimum inhibitory concentration of 11 clinical strains of Gram-positive bacteria, 6 of Gram-negative bacteria and 5 of anaerobic bacteria was 0.39 microgram/ml. FMOX showed the strongest, most comprehensive antibacterial action among the drugs tested. 2. Thirty patients received FMOX. Clinical effectiveness was evaluated in 28 patients, and clinical usefulness and safety in 30. 3. The clinical efficacy rate ('excellent' and 'good') was 75% (21/28). 4. As for bacteriological response, bacterial elimination rates were 67% for Gram-positive bacteria, 100% for Gram-negative bacteria, 100% for anaerobic bacteria and 100% for mixed infections. 5. Side effects occurred in 2 (6%) patients: drug eruption and diarrhea in 1 patient each. These symptoms improved rapidly after discontinuation of the drug. 6. Although abnormal clinical test results were found in 7 (23%) patients, i.e., increases in GOT and GPT in 2, in GPT in 4 and in BUN in 1, they were transient. 7. The usefulness of FMOX was assessed in light of its efficacy and safety. It was highly satisfactory in 14 patients, satisfactory in 11, relatively satisfactory in 1, unsatisfactory in 2 and highly unsatisfactory in 2, and rate of usefulness was 83%. FMOX is considered to be highly useful for the treatment of severe acute tonsillitis.
Insights
Flomoxef (FMOX) demonstrates strong antibacterial action against acute tonsillitis pathogens. Clinical trials show high efficacy and usefulness, with a 75% clinical efficacy rate and a 83% usefulness rate.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Microbiology
Background:
- Acute tonsillitis is a common infection requiring effective antibiotic treatment.
- Flomoxef (FMOX) is a potential therapeutic agent for bacterial infections.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of Flomoxef (FMOX) in treating acute tonsillitis.
- To determine the antimicrobial susceptibility of clinical strains to FMOX.
Main Methods:
- Assessed the 80% minimum inhibitory concentration (MIC) of FMOX against Gram-positive, Gram-negative, and anaerobic bacteria.
- Conducted a clinical trial involving 30 patients with acute tonsillitis treated with FMOX.
- Evaluated clinical effectiveness, bacteriological response, safety, and overall usefulness of FMOX.
Main Results:
- FMOX exhibited broad-spectrum antibacterial activity with an 80% MIC of 0.39 microgram/ml.
- Clinical efficacy rate was 75% (21/28), with high bacterial elimination rates (67-100%).
- Adverse events were mild (6%), and the overall usefulness rate was 83%.
Conclusions:
- Flomoxef (FMOX) demonstrates significant clinical efficacy and a favorable safety profile for acute tonsillitis.
- FMOX is considered a highly useful antibiotic for treating severe acute tonsillitis.